Page 119 - Read Online

44. Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, 60. Mertens K, Bolcaen J, Ham H, Deblaere K, Van den Broecke C,
Fujimoto Y, Oji Y, Oka Y, Shimosegawa E, Morita S, Hatazawa J, Boterberg T, De Vos F, Goethals I. The optimal timing for
Sugiyama H, Hashimoto N, Yoshimine T. Use of (11)C‑methionine imaging brain tumours and other brain lesions with 18F‑labelled
PET parametric response map for monitoring WT1 immunotherapy fluoromethylcholine: a dynamic positron emission tomography
response in recurrent malignant glioma. J Neurosurg study. Nucl Med Commun 2012;33:954‑9.
2012;116:835‑42. 61. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F, Lin X. Misdiagnoses
45. van Waarde A, Elsinga PH. Proliferation markers for the of 11C‑choline combined with 18F‑FDG PET imaging in brain
differential diagnosis of tumor and inflammation. Curr Pharm Des tumours. Nucl Med Commun 2008;29:354‑8.
2008;14:3326‑39. 62. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N,
46. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch‑Schmidtke R, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of
Schwaiger M, Stöcklin G. Synthesis and radiopharmacology of 3,4‑dihydroxy‑6‑18F‑fluoro‑L‑phenylalanine PET/CT on managing
O‑(2‑[18F] fluoroethyl)‑L‑tyrosine for tumor imaging. J Nucl Med patients with brain tumors: the referring physician’s perspective.
1999;40:205‑12. J Nucl Med 2012;53:393‑8.
47. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, 63. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, Herzog H,
Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Shah NJ, Fink GR, Coenen HH, Langen KJ. Role of O‑(2‑(18)
Floeth FW, Langen KJ. Diagnostic performance of 18F‑FET PET in F‑fluoroethyl)‑L‑tyrosine PET for differentiation of local recurrent brain
newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med metastasis from radiation necrosis. J Nucl Med 2012;53:1367‑74.
2013;54:229‑35. 64. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G,
48. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance Grigg A, Callahan J, Hicks RJ. Comparative PET study using F‑18
of 18F‑fluoro‑ethyl‑tyrosine (18F‑FET) PET for the differential FET and F‑18 FDG for the evaluation of patients with suspected
diagnosis of primary brain tumor: a systematic review and brain tumour. J Clin Neurosci 2010;17:43‑9.
Metaanalysis. J Nucl Med 2012;53:207‑14. 65. Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J,
49. Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW,
Kretzschmar HA, Tonn JC, Tatsch k. Analysis of 18F‑FET PET for la Fougère C. MRI‑suspected low‑grade glioma: is there a need
grading of recurrent gliomas: is evaluation of uptake kinetics superior to perform dynamic FET PET? Eur J Nucl Med Mol Imaging
to standard methods? J Nucl Med 2006;47:393‑403. 2012;39:1021‑9.
50. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, 66. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ,
Sabel M, Langen KJ. Response assessment of bevacizumab in patients Langen KJ. Prognostic value of 18F‑fluoroethyl‑L‑tyrosine PET
with recurrent malignant glioma using [18F] Fluoroethyl‑L‑tyrosine and MRI in small nonspecific incidental brain lesions. J Nucl Med
PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2008;49:730‑7.
2013;40:22‑33. 67. Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A,
51. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Otani T, Kurihara H, Sasaki T, Endo K. Gliomatosis cerebri evaluated
Value of O‑(2‑[18F] fluoroethyl)‑ L‑tyrosine PET for the diagnosis of by 18Falpha‑methyl tyrosine positron‑emission tomography.
recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464‑70. Neuroradiology 2003;45:700‑7.
52. Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, 68. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F,
Topakian R, Aigner RM. Is there a place for FET PET in the initial Schwaiger M, Molls M, Wester HJ, Weber WA. An interindividual
evaluation of brain lesions with unknown significance? Eur J Nucl comparison of O‑(2‑[18F] fluoroethyl)‑L‑tyrosine (FET)‑ and
Med Mol Imaging 2010;37:1521‑8. L‑[methyl‑11C] methionine (MET)‑PET in patients with brain gliomas
53. Pichler R, Wurm G, Nussbaumer K, Kalev O, Silyé R, Weis S. and metastases. Int J Radiat Oncol Biol Phys 2011;81:1049‑58.
Sarcoidois and radiation‑induced astrogliosis causes pitfalls in 69. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G,
neuro‑oncologic positron emission tomography imaging by Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T,
O‑(2‑[18F] fluoroethyl)‑L‑tyrosine. J Clin Oncol 2010;28:e753‑5. Jacobs AH, Stockhammer G. O‑(2‑18F‑fluoroethyl)‑L‑tyrosine PET
54. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, predicts failure of antiangiogenic treatment in patients with recurrent
Herholz K, Pietrzyk U. F‑Dopa as an amino acid tracer to detect high‑grade glioma. J Nucl Med 2011;52:856‑64.
brain tumors. J Nucl Med 1996;37:1180‑2. 70. Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM,
55. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Galldiks N. The use of O‑(2‑18F‑fluoroethyl)‑L‑tyrosine PET for
Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. treatment management of bevacizumab and irinotecan in patients
Correlation of 6‑18F‑fluoro‑L‑dopa PET uptake with proliferation with recurrent high‑grade glioma: a cost‑effectiveness analysis.
and tumor grade in newly diagnosed and recurrent gliomas. J Nucl J Nucl Med 2013;54:1217‑22.
Med 2010;51:1532‑8. 71. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J,
56. Karunanithi S, Sharma P, Kumar A, Khangembam BC, Pope W. 18F‑FDOPA PET/MRI fusion in patients with primary/
Bandopadhyaya GP, Kumar R, Goenka A, Gupta DK, Malhotra A, recurrent gliomas: initial experience. Eur J Radiol 2009;71:242‑8.
Bal C. Comparative diagnostic accuracy of contrast‑enhanced 72. Spence AM, Muzi M, Link JM, O’Sullivan F, Eary JF, Hoffman JM,
MRI and (18)F‑FDOPA PET‑CT in recurrent glioma. Eur Radiol Shankar LK, Krohn KA. NCI‑sponsored trial for the evaluation of safety
2013;23:2628‑35. and preliminary efficacy of 3’‑deoxy‑3’‑[18F] fluorothymidine (FLT)
57. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, as a marker of proliferation in patients with recurrent gliomas:
Higashi T, Oya N, Mukai T, Hojo M, Hashimoto N, Manabe T, preliminary efficacy studies. Mol Imaging Biol 2009;11:343‑55.
Hiraoka M, Togashi K. Evaluation of primary brain tumors with 73. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T,
FLT‑PET: usefulness and limitations. Clin Nucl Med 2006;31:774‑80. Czernin J, Phelps ME, Chen W, Ellingson BM. 18F‑FDOPA and
58. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, 18F‑FLT positron emission tomography parametric response
Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting maps predict response in recurrent malignant gliomas treated with
treatment response of malignant gliomas to bevacizumab and bevacizumab. Neuro Oncol 2012;14:1079‑89.
irinotecan by imaging proliferation with [18F] fluorothymidine 74. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB,
positron emission tomography: a pilot study. J Clin Oncol Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME,
2007;25:4714‑21. Chen W. 3’‑deoxy‑3’‑18F‑fluorothymidine PET and MRI for early
59. Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, survival predictions in patients with recurrent malignant glioma
Tamiya T. Usefulness of FDG, MET and FLT‑PET studies for treated with bevacizumab. J Nucl Med 2012;53:29‑36.
the management of human gliomas. J Biomed Biotechnol 75. Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P,
2012;2012:205818. Heerschap A, van der Graaf WT, Grotenhuis JA, Oyen WJ.

Neuroimmunol Neuroinflammation | Volume 1 | Issue 3 | December 2014 113